Gilead’s Lenacapavir, Takeda’s Maribavir Due For Oral Explanations At EMA
The sponsors of four drugs were due or possibly due to appear before the European Medicines Agency to explain why their respective products merit EU-wide approval.
You may also be interested in...
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
After more review of clinical trial data, the myeloma drug’s sponsor wants to talk to the FDA again, but Oncopeptides execs said they cannot disclose the scientific details that led to the decision.